1 citations
,
February 2025 in “Journal of the American Academy of Dermatology” Most men prefer keeping their eyebrows over scalp hair.
4 citations
,
September 2025 in “Journal of the American Academy of Dermatology” 15 citations
,
December 2018 in “International journal of environmental research and public health/International journal of environmental research and public health” EGCG may help treat alopecia areata by blocking certain immune responses and reducing specific harmful immune cells.
9 citations
,
January 2006 in “Cutaneous and ocular toxicology” L-cystine, D-pantothenat, and miliacin together significantly boost keratinocyte growth and metabolism.
21 citations
,
October 2023 in “Journal of Dermatological Treatment” Baricitinib effectively reduces hair loss in severe alopecia areata and is generally safe.
3 citations
,
February 2025 in “Journal of Dermatological Treatment” Hair regrowth in Alopecia Areata patients leads to increased satisfaction and reduced stress.
September 2023 in “Journal of the American Academy of Dermatology” CTP-543 significantly improved eyebrow and eyelash regrowth and patient satisfaction in adults with alopecia areata.
July 2024 in “Journal of Investigative Dermatology” ITK inhibitors may effectively treat alopecia areata.
15 citations
,
January 2025 in “Journal of the European Academy of Dermatology and Venereology” Ritlecitinib is effective and safe for treating alopecia areata, promoting significant hair regrowth.
7 citations
,
October 2024 in “Journal of the American Academy of Dermatology” Continued ritlecitinib treatment helps sustain hair regrowth in alopecia areata patients.
4 citations
,
March 2025 in “The Journal of Dermatology” Ritlecitinib is effective and safe for hair regrowth in Asian patients with alopecia areata.
January 2022 in “Dermatology Review” Higher IL-31 levels are linked to worse itching in chronic kidney disease patients.
January 2022 in “Skin Pharmacology and Physiology” Higher STAT3 levels are found in hair loss areas, but not linked to hair loss severity.
18 citations
,
January 2021 in “Theranostics” The targeted nanohybrids effectively reduced psoriasis symptoms and improved skin health.
2 citations
,
September 2024 in “Journal of the American Academy of Dermatology” Deuruxolitinib significantly helps regrow scalp hair in adults with moderate to severe alopecia areata.
2 citations
,
April 2023 in “Polymers” The study created 3D-printed pills that effectively release a hair loss treatment drug over 24 hours.
1 citations
,
September 2023 in “Journal of the American Academy of Dermatology” Continued ritlecitinib treatment can lead to hair regrowth in some patients with alopecia areata who initially don't respond.
April 2024 in “Frontiers in pharmacology” Brepocitinib 30mg is most effective for moderate-to-severe alopecia areata, but ritlecitinib 50mg may offer a better balance of safety and effectiveness.
May 2022 in “Journal of the Dermatology Nurses' Association” The convention highlighted the importance of comprehensive patient care and early diagnosis in dermatology.
December 2022 in “Scientific Reports” Compound 4 is a promising treatment for hair loss with low toxicity.
The study concluded that Frontal fibrosing alopecia can affect younger people, is often missed in men, and may be autoimmune-related.
48 citations
,
March 2020 in “Stem Cell Research & Therapy” Using a collagen sponge scaffold helps stem cells become more like skin cells.
February 2026 in “International Journal of Molecular Sciences” 3D human skin models show promise for dermatology but face challenges in standardization and cost.
24 citations
,
December 2023 in “Gels” 3D-printed hydrogels show promise in medicine but face challenges in resolution, cell viability, cost, and regulations.
1 citations
,
October 2025 in “International Journal of Dermatology” Ritlecitinib improves emotional well-being and activity levels in alopecia areata patients.
3 citations
,
February 2024 in “Journal of the American Academy of Dermatology” Topical tofacitinib cream may help treat certain hair loss conditions with fewer risks.
78 citations
,
March 2017 in “JAMA Dermatology” Tofacitinib helped regrow hair in people with severe alopecia, but side effects occurred and benefits stopped after treatment ended.
2 citations
,
May 2017 in “Journal of the American Academy of Dermatology” Tofacitinib helped a 19-year-old regrow hair after other treatments failed.
September 2024 in “Drugs & Therapy Perspectives” Ritlecitinib effectively regrows hair in severe alopecia areata and is well tolerated.
March 2023 in “PARIPEX INDIAN JOURNAL OF RESEARCH” Tofacitinib helped regrow hair in most patients with severe hair loss.